Pan Tumour Nivolumab Rollover Study

Official Title

Pan-Tumour Study for Long Term Follow-up of Cancer Survivors Who Have Participated in Trials Investigating Nivolumab


Main Objective of this study is to examine long-term safety of nivolumab in participants on treatment and in follow up.

Trial Description

Primary Outcome:

  • Incidence of Adverse Events (AEs)
  • Incidence of drug related AEs
  • Incidence of AEs leading to Discontinuation
  • Incidence of Serious Adverse Events (SAEs)
  • Incidence of Select AEs
  • Incidence of Immune-Mediated AEs
  • Incidence of Death

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society